FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386295852> ?p ?o ?g. }

• W4386295852 endingPage "e007118" @default.
• W4386295852 startingPage "e007118" @default.
• W4386295852 abstract "Background Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and in the European Union for patients ≥26 years with R/R B-ALL. After 2 years of follow-up in ZUMA-3, the overall complete remission (CR) rate (CR+CR with incomplete hematological recovery (CRi)) was 73%, and the median overall survival (OS) was 25.4 months in 78 Phase 1 and 2 patients with R/R B-ALL who received the pivotal dose of brexu-cel. Outcomes by prior therapies and subsequent allogeneic stem cell transplantation (alloSCT) are reported. Methods Eligible adults had R/R B-ALL and received one infusion of brexu-cel (1×10⁶ CAR T cells/kg) following conditioning chemotherapy. The primary endpoint was the CR/CRi rate per central review. Post hoc subgroup analyses were exploratory with descriptive statistics provided. Results Phase 1 and 2 patients (N=78) were included with median follow-up of 29.7 months (range, 20.7–58.3). High CR/CRi rates were observed across all prior therapy subgroups examined: 1 prior line of therapy (87%, n=15) and ≥2 prior lines (70%, n=63); prior blinatumomab (63%, n=38) and no prior blinatumomab (83%, n=40); prior inotuzumab (59%, n=17) and no prior inotuzumab (77%, n=61); and prior alloSCT (76%, n=29) and no prior alloSCT (71%, n=49). The frequency of Grade ≥3 cytokine release syndrome, neurological events, and treatment-related Grade 5 adverse events were largely similar among prior therapy subgroups. Median duration of remission (DOR) in responders with (n=14) and without (n=43) subsequent alloSCT was 44.2 (95% CI, 8.1 to not estimable (NE)) and 18.6 months (95% CI, 9.4 to NE); median OS was 47.0 months (95% CI, 10.2 to NE) and not reached (95% CI, 23.2 to NE), respectively. Median DOR and OS were not reached in responders without prior or subsequent alloSCT (n=22). Conclusions In ZUMA-3, adults with R/R B-ALL benefited from brexu-cel, regardless of prior therapies and subsequent alloSCT status, though survival appeared better in patients without certain prior therapies and in earlier lines of therapy. Additional studies are needed to determine the impact prior therapies and subsequent alloSCT have on outcomes of patients who receive brexu-cel." @default.
• W4386295852 created "2023-08-31" @default.
• W4386295852 creator A5003069482 @default.
• W4386295852 creator A5008125030 @default.
• W4386295852 creator A5009635192 @default.
• W4386295852 creator A5012940331 @default.
• W4386295852 creator A5013177563 @default.
• W4386295852 creator A5014892222 @default.
• W4386295852 creator A5017200652 @default.
• W4386295852 creator A5021579716 @default.
• W4386295852 creator A5025137989 @default.
• W4386295852 creator A5027316096 @default.
• W4386295852 creator A5030793783 @default.
• W4386295852 creator A5031216970 @default.
• W4386295852 creator A5035175326 @default.
• W4386295852 creator A5037299848 @default.
• W4386295852 creator A5039996784 @default.
• W4386295852 creator A5041486255 @default.
• W4386295852 creator A5049413660 @default.
• W4386295852 creator A5049910941 @default.
• W4386295852 creator A5064294460 @default.
• W4386295852 creator A5071733656 @default.
• W4386295852 creator A5071844603 @default.
• W4386295852 creator A5076973611 @default.
• W4386295852 creator A5079582306 @default.
• W4386295852 creator A5082924494 @default.
• W4386295852 creator A5089428686 @default.
• W4386295852 creator A5089893290 @default.
• W4386295852 creator A5090694142 @default.
• W4386295852 creator A5091739351 @default.
• W4386295852 creator A5092719367 @default.
• W4386295852 date "2023-08-01" @default.
• W4386295852 modified "2023-09-30" @default.
• W4386295852 title "Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3" @default.
• W4386295852 cites W2082708772 @default.
• W4386295852 cites W2107925822 @default.
• W4386295852 cites W2395942880 @default.
• W4386295852 cites W2516611622 @default.
• W4386295852 cites W2591709377 @default.
• W4386295852 cites W2931981435 @default.
• W4386295852 cites W2963636186 @default.
• W4386295852 cites W2985081230 @default.
• W4386295852 cites W3113994324 @default.
• W4386295852 cites W3117342710 @default.
• W4386295852 cites W3169193862 @default.
• W4386295852 cites W3185183014 @default.
• W4386295852 cites W4226180206 @default.
• W4386295852 cites W4286449704 @default.
• W4386295852 cites W4311665098 @default.
• W4386295852 doi "https://doi.org/10.1136/jitc-2023-007118" @default.
• W4386295852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37648261" @default.
• W4386295852 hasPublicationYear "2023" @default.
• W4386295852 type Work @default.
• W4386295852 citedByCount "0" @default.
• W4386295852 crossrefType "journal-article" @default.
• W4386295852 hasAuthorship W4386295852A5003069482 @default.
• W4386295852 hasAuthorship W4386295852A5008125030 @default.
• W4386295852 hasAuthorship W4386295852A5009635192 @default.
• W4386295852 hasAuthorship W4386295852A5012940331 @default.
• W4386295852 hasAuthorship W4386295852A5013177563 @default.
• W4386295852 hasAuthorship W4386295852A5014892222 @default.
• W4386295852 hasAuthorship W4386295852A5017200652 @default.
• W4386295852 hasAuthorship W4386295852A5021579716 @default.
• W4386295852 hasAuthorship W4386295852A5025137989 @default.
• W4386295852 hasAuthorship W4386295852A5027316096 @default.
• W4386295852 hasAuthorship W4386295852A5030793783 @default.
• W4386295852 hasAuthorship W4386295852A5031216970 @default.
• W4386295852 hasAuthorship W4386295852A5035175326 @default.
• W4386295852 hasAuthorship W4386295852A5037299848 @default.
• W4386295852 hasAuthorship W4386295852A5039996784 @default.
• W4386295852 hasAuthorship W4386295852A5041486255 @default.
• W4386295852 hasAuthorship W4386295852A5049413660 @default.
• W4386295852 hasAuthorship W4386295852A5049910941 @default.
• W4386295852 hasAuthorship W4386295852A5064294460 @default.
• W4386295852 hasAuthorship W4386295852A5071733656 @default.
• W4386295852 hasAuthorship W4386295852A5071844603 @default.
• W4386295852 hasAuthorship W4386295852A5076973611 @default.
• W4386295852 hasAuthorship W4386295852A5079582306 @default.
• W4386295852 hasAuthorship W4386295852A5082924494 @default.
• W4386295852 hasAuthorship W4386295852A5089428686 @default.
• W4386295852 hasAuthorship W4386295852A5089893290 @default.
• W4386295852 hasAuthorship W4386295852A5090694142 @default.
• W4386295852 hasAuthorship W4386295852A5091739351 @default.
• W4386295852 hasAuthorship W4386295852A5092719367 @default.
• W4386295852 hasBestOaLocation W43862958521 @default.
• W4386295852 hasConcept C121332964 @default.
• W4386295852 hasConcept C121608353 @default.
• W4386295852 hasConcept C126322002 @default.
• W4386295852 hasConcept C142424586 @default.
• W4386295852 hasConcept C143998085 @default.
• W4386295852 hasConcept C203014093 @default.
• W4386295852 hasConcept C2777701055 @default.
• W4386295852 hasConcept C2778020697 @default.
• W4386295852 hasConcept C2778461978 @default.
• W4386295852 hasConcept C2780850621 @default.
• W4386295852 hasConcept C2781107101 @default.
• W4386295852 hasConcept C2909962599 @default.
• W4386295852 hasConcept C2911091166 @default.

• next